Metabolomics in Chronic Kidney Disease: The Emerging Role in Detection and Diagnosis of Mineral and Bone Disorders
Abstract
Chronic kidney disease (CKD) affects over 10% of the global population and is increasingly prevalent, placing a substantial strain on healthcare systems. In Malaysia, CKD prevalence rose from 9.05% in 2011 to 15.48% in 2018, largely driven by diabetes mellitus. CKD often progresses to mineral and bone disorders (CKD-MBD), a condition starting as early as stage 3a CKD, characterized by disturbances in mineral and bone metabolism that contribute to significant morbidity and mortality. Current diagnostic methods for CKD-MBD, including bone biopsy and imaging, have limitations such as invasiveness, cost, and insufficient sensitivity. Biochemical markers offer some insight but are often not robust enough for the accurate detection and diagnosis of the disease. New protein biomarkers such as sKhloto and FGF23 are restricted by methodological issues and conflicting research outcomes. Metabolomics, the study of small molecule metabolites, provides a promising alternative. By analyzing metabolic profiles in biological samples, metabolomics reveals detailed biochemical changes linked to CKD-MBD. Recent studies have identified certain key metabolites associated with CKD-MBD. Despite some inconsistencies existing across studies, metabolomics, especially when combined with advanced techniques and machine learning, may hold great potential for discovering novel biomarkers for CKD-MBD. This review provides a comprehensive overview of the emerging role of metabolomic profiling in the detection and diagnosis of CKD-MBD. It aimed to enhance the understanding of the disease at a molecular level and explore new avenues for improving the diagnosis and management of this complex condition.
Keywords
Full Text:
PDFReferences
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011) 2022;12:7-11.
Saminathan TA, Hooi LS, Mohd Yusoff MF, Ong LM, Bavanandan S, Rodzlan Hasani WS, et al. Prevalence of chronic kidney disease and its associated factors in Malaysia; Findings from a nationwide population-based cross-sectional study. BMC Nephrol 2020;21.
Waziri B, Duarte R, Naicker S. Chronic kidney disease–mineral and bone disorder (CKD-MBD): Current perspectives. Int J Nephrol Renovasc Dis 2019;12:263-276.
Shah A, Hashmi MF, Aeddula NR. Chronic kidney disease-mineral bone disorder (CKD-MBD). Treasure Island (FL): StatPearls Publishing; 2024.
Sridharan K. Chronic kidney disease mineral and bone disorder: a guide for general practice. Aust J Gen Pract 2023;52:52–7.
Aguilar A, Gifre L, Ureña-Torres P, Carrillo-López N, Rodriguez-García M, Massó E, et al. Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis. Front Physiol 2023;14:11777829.
Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO Chronic kidney disease–mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int 2017;92.
Andrukhova O, Schüler C, Bergow C, Petric A, Erben RG. Augmented fibroblast growth factor-23 secretion in bone locally contributes to impaired bone mineralization in chronic kidney disease in mice. Front Endocrinol (Lausanne) 2018;9:311.
Kawakami K, Takeshita A, Furushima K, Miyajima M, Hatamura I, Kuro-O M, et al. Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease. Sci Rep 2017;7:40534.
Yamada S, Giachelli CM. Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho. Bone 2017;100:87–93.
Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 2016;67:559–66.
Bembem K, Singh T, Singh NP, Saxena A, Jain SL. Bone histo-morphology in chronic kidney disease mineral bone disorder. Indian J Hematol Blood Transfus 2016;33:603-10.
Dousdampanis P, Trigka K. The importance of bone biopsy in chronic kidney disease-Mineral bone disorders. Saudi J Kidney Dis Transpl 2017;28:992–6.
Evenepoel P, D’Haese P, Bacchetta J, Cannata-Andia J, Ferreira A, Haarhaus M, et al. Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative - a position paper. Nephrol Dial Transplantation 2017;32:1608–13.
Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Am J Kidney Dis2017;70:737–51.
Pimentel A, Bover J, Elder G, Cohen-Solal M, Ureña-Torres PA. The use of imaging techniques in chronic kidney disease-mineral and bone disorders (CKD-MBD)-A systematic review. Diagnostics (Basel) 2021;11:772.
Nizet A, Cavalier E, Stenvinkel P, Haarhaus M, Magnusson P. Bone alkaline phosphatase: An important biomarker in chronic kidney disease - mineral and bone disorder. Clin Chim Acta 2020;501:198–206.
Salam S, Gallagher O, Gossiel F, Paggiosi M, Khwaja A, Eastell R. Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy. J Am Soc Nephrol 2018;29:1557–65.
Smout D, Jørgensen HS, Cavalier E, Evenepoel P. Clinical utility of bone turnover markers in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2022;31:332–8.
Jørgensen HS, Behets G, Viaene L, Bammens B, Claes K, Meijers B, et al. Diagnostic accuracy of noninvasive bone turnover markers in renal osteodystrophy. Am J Kidney Dis 2022;79:667-76.
Hlaing TT, Compston JE. Biochemical markers of bone turnover - uses and limitations. Ann Clin Biochem 2014;51:189–202.
Fusaro M, Barbuto S, Gallieni M, Cossettini A, Re Sartò GV, Cosmai L, et al. Real-world usage of chronic kidney disease - mineral bone disorder (CKD-MBD) biomarkers in nephrology practices. Clin Kidney J 2023;17.
Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370–8.
Dhayat NA, Ackermann D, Pruijm M, Ponte B, Ehret G, Guessous I, et al. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. Kidney Int 2016;90:648–57.
Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010 Sep 1;21(9):1427–35.
Heijboer AC, Cavalier E. The Measurement and interpretation of fibroblast growth factor 23 (FGF23) concentrations. Calcif Tissue Int 2023;112:258-70.
Damasiewicz MJ, Lu ZX, Kerr PG, Polkinghorne KR. The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort. BMC Nephrol 2018;19.
Martín-Vírgala J, Martín-Carro B, Fernández-Villabrille S, Ruiz-Torres MP, Gómez-Alonso C, Rodríguez-García M, et al. Soluble Klotho, a potential biomarker of chronic kidney disease-mineral bone disorders involved in healthy ageing: lights and shadows. Int J Mol Sci 2024;25.
Seiler S, Wen M, Roth HJ, Fehrenz M, Flügge F, Herath E, et al. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int 2013;83:121–8.
Podgórska B, Wielogórska-Partyka M, Godzieñ J, Sieñmiska J, Ciborowski M, Szelachowska M, et al. Applications of metabolomics in calcium metabolism disorders in humans. Int J Mol Sci 2022;23.
Sun M, Wu X, Yu Y, Wang L, Xie D, Zhang Z, et al. Disorders of calcium and phosphorus metabolism and the proteomics/metabolomics-based research. Front Cell Dev Biol 2020;8:576110.
Danilova EY, Maslova AO, Stavrianidi AN, Nosyrev AE, Maltseva LD, Morozova OL. CKD urine metabolomics: Modern concepts and approaches. Pathophysiology 2023;30:443–66.
Lee AM, Hu J, Xu Y, Abraham AG, Xiao R, Coresh J, et al. Using machine learning to identify metabolomic signatures of pediatric chronic kidney disease etiology. J Am Soc Nephrol 2022;33:375–86.
Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S, et al. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther 2023;8:132.
Vivanco F, Barderas MG, Laborde CM, Posada M, De La Cuesta F, et al. Metabolomic profiling for identification of novel potential biomarkers in cardiovascular diseases. J Biomed Biotechnol 2011;2011.
Park J, Shin Y, Kim TH, Kim DH, Lee A. Plasma metabolites as possible biomarkers for diagnosis of breast cancer. PLoS One 2019;14.
Jin Q, Ma RCW. Metabolomics in diabetes and diabetic complications: insights from epidemiological studies. Cells 2021;10:2832.
Shah VO, Townsend RR, Feldman HI, Pappan KL, Kensicki E, Vander Jagt DL. Plasma metabolomic profiles in different stages of CKD. Clin J Am Soc Nephrol 2013;8:363–70.
Wu Q, Lai X, Zhu Z, Hong Z, Dong X, Wang T, et al. Evidence for chronic kidney disease-mineral and bone disorder associated with metabolic pathway changes. Medicine (United States). 2015;94.
Yonova D, Dukova P. Changes of serum bone markers in CAPD and hemodialysis patients. Hippokratia 2007;11:199.
Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 2005;26:97-122..
Sanchez-Gimenez R, Peiró ÓM, Bonet G, Carrasquer A, Fragkiadakis GA, Bulló M, et al. TCA cycle metabolites associated with adverse outcomes after acute coronary syndrome: mediating effect of renal function. Front Cardiovasc Med 2023;10.
Shen Q, Xiang W, Ye S, Lei X, Wang L, Jia S, et al. Plasma metabolite biomarkers related to secondary hyperparathyroidism and parathyroid hormone. J Cell Biochem 2019;120:15766–75.
Gan L, Wang L, Li W, Zhang Y, Xu B. Metabolomic profile of secondary hyperparathyroidism in patients with chronic kidney disease stages 3-5 not receiving dialysis. Front Endocrinol (Lausanne) 2024;15.
Madella AM, Van Bergenhenegouwen J, Garssen J, Masereeuw R, Overbeek SA. Microbial-derived tryptophan catabolites, kidney disease and gut inflammation. Toxins 2022;14:645.
Al Saedi A, Sharma S, Summers MA, Nurgali K, Duque G. The multiple faces of tryptophan in bone biology. Exp Gerontol 2020;129;110778.
Anaya JM, Bollag WB, Hamrick MW, Isales CM. The role of tryptophan metabolites in musculoskeletal stem cell aging. Int J Mol Sci 2020;21:1–13.
Pierce JL, Roberts RL, Yu K, Kendall RK, Kaiser H, Davis C, et al. Kynurenine suppresses osteoblastic cell energetics in vitro and osteoblast numbers in vivo. Exp Gerontol 2019;130:110818-8.
Gao Y, Li Y, Duan X, Wang Q, Zhang H. Research progress on the relationship between IS and kidney disease and its complications. Int Urol Nephrol 2022;54:2881–90.
Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M, et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007;71:738–43.
Lee HJ, Mun HC, Lewis NC, Crouch MF, Culverston EL, Mason RS, et al. Allosteric activation of the extracellular Ca2+-sensing receptor by L-amino acids enhances ERK1/2 phosphorylation. Biochem J 2007;404:141–9.
Hannan FM, Kallay E, Chang W, Brandi ML, Thakker R V. Calcium-sensing receptor in physiology and in calcitropic and non-calcitropic diseases. Nat Rev Endocrinol 2018;15:33-51
Yang Y, Ye Y, Deng Y, Gao L. Uridine and its role in metabolic diseases, tumors, and neurodegenerative diseases. Front Physiol 2024;15:1360891.
Pacheco-Alvarez D, Solórzano-Vargas RS, Del Río AL. Biotin in metabolism and its relationship to human disease. Arch Med Res 2002;33:439–47.
Dator R, Villalta PW, Thomson N, Jensen J, Hatsukami DK, Stepanov I, et al. Metabolomics profiles of smokers from two ethnic groups with differing lung cancer risk. Chem Res Toxicol 2020;33:2087–98.
McGee EE, Zeleznik OA, Balasubramanian R, Hu J, Rosner BA, Wactawski-Wende J, et al. Differences in metabolomic profiles between Black and White women in the U.S.: Analyses from two prospective cohorts. Eur J Epidemiol 2024;39:653–65.
Kim S, Kim J, Yun EJ, Kim KH. Food metabolomics: from farm to human. Curr Opin Biotechnol 2016;37:16–23.
Noerman S, Landberg R. Blood metabolite profiles linking dietary patterns with health-Toward precision nutrition. J Intern Med 2023;293:408–32.
Nyamundanda G, Gormley IC, Fan Y, Gallagher WM, Brennan L. MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach. BMC Bioinformatics 2013;14:338.
Kritmetapak K, Pongchaiyakul C. Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications. Int J Nephrol 2019;2019:5496710.
Baptista AL, Padilha K, Malagrino PA, Venturini G, Zeri ACM, dos Reis LM, et al. Potential biomarkers of the turnover, mineralization, and volume classification: results using nmr metabolomics in hemodialysis patients. JBMR Plus 2020;4.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.